BPMC - Earnings call transcript Q3 2020 | Blueprint Medicines Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Blueprint Medicines Third Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. hand of over Blueprint to today, your like Hodous Kristin Medicines. now the to conference speaker I’d Thank you. Please go ahead, ma'am.

Kristin Hodous

conference financial Thank And you, which today. operating outlines XXXX to we press welcome everyone. morning, results and discuss to Blueprint the issued Operator. Medicines' third release, Good a call. This morning, plan we topics quarter

Today, to our business Medicines and Medical joining the also on will website Commercial call Mike be reviewing we'll can highlights; the access that Officer, our Albers, Officer Jeff will press You Q&A. and call, Chief Chief XXXX the discuss of update; will our Boral, by our commercial release, Officer, Financial a results; the Chief going our slides Christy at Officer, Landsittel, financial section our review is as www.blueprintmedicines.com. third well as Executive will Investors today Chief available Rossi, for be our quarter provide Andy Dr. Blueprint

I remind results forth other could Before call expressed on statements. most as or risks, make events the in various those other that with get a any of filings XX-Q on result of SEC. the forward-looking everyone Actual any we will the materially include like from with section conference by make we factors, started, filed or differ those this we recent including Factors uncertainties statements form statements and Risk report forward-looking set that would our implied quarterly SEC and to

our statements. subsequent or obligation specifically be relied update as revise any on views In representing addition, not today represents of to any forward-looking and this our call as any disclaim should forward-looking date. of as only made statements We any upon views

Now here's CEO, Jeff our Albers.

Jeff Albers

everyone. progress made morning, good today entire the to past on a significant you portfolio. this quarter we our It's and pleasure across update Kristin, Thanks,

commercial areas and of launched our expertise platform. have mastocytosis; with two, our previously, been three, products, from our new programs investigational and to registrational strategic pipeline building systemic One, medicines multiple continuing advancing new our As our we've focus as discussed key strengthen threefold. research we've

quarter, of third substantial we and as the as opportunities strength of progress which the our last growth in well particular, During for month whole these portfolio really focus across highlights positions ahead. a continued made and areas, each the

with SM. Let me on start mastocytosis focus our systemic or

reported data consistent As patients a both in results and The September, the trials medical advanced rates In and of need overall advanced reductions response remission is overall high disease the were AVYAKIT with with survival. spectrum reminder, spans top EXPLORER SM studies positive entire both advanced from profound median clinical announced and PATHFINDER across the in SM. forms and across benefit clinical line cell including significant complete and our prolong non durable of previously urgent. we results, mass and showing burden,

need the Importantly, once XXX once XX of urgent pioneer also dose, earlier avapritinib's safety to us advanced options. will level. with better Non NDA these we rapidly advanced an daily part are this Collectively, favorable dose a for again the at impact with our foundation advanced on compiling at milligram to presented avapritinib They're data FDA were this in in SM, data on transformative submit indolent response year. day high and filing based showed and the for validating priority safety data patients are which the showing top data the track data underscore milligram improved supplemental the profile the of SM, one per remains dose. profile quarter. rate SM or This this who compelling capture at treatment decision comprise the additional our

from We expanding enrollment enthusiasm as as more existing from well key and continue of investigators, broadly. acceleration see to be opinion encouraged to leaders

the FDA received cancer, we September, of in progress; significant non a commercial cell patients for positive and GIST, GAVRETO as milestone metastatic company. lung for our approval for precision of solidifies a Blueprint truly and is small AVYAKIT fusion adult This community. integrated lung alpha Blueprint red treatment the our Medicines this second PDGFRA cancer driven for year medicine following with biopharmaceutical to Turning approval

As moment, transformative discuss whom leverage the launch collaboration third Roche, a in as pralsetinib expertise in for of of the signed we quarter. the up we're Christy a GAVRETO will ramping with commercial also we

an In addition, cancers. first we thyroid expansion ret to of quarter XXXX the FDA decision forward by with potential the anticipated altered look the GAVRETO for

virtual cancer. EGFR our BLU-XXX, Finally, BLU-XXX preclinical inhibitors. we our common target EGFR in the September, to platform. lung mutant was resistant inhibit from for robust osimertinib driven we to continue programs At and emerging presented inhibitor designed new most specifically triple mechanisms on the strengthen resistance Congress research first potently with important generation for ESMO our pipeline treatment data to

with excluded while type lines. Importantly, benefit safety may enable as a profile strategies earlier as patients This in has wild retaining the treatment provide disease, treatment resistant selectivity. combination and to profile potential well to that keinem

of in to As the double of we a BLU-XXX double the enable advance a prevent of in therapies early and nominate we combination clinic the to transformative with announced patient compounds as XXXX. broad resistance complimentary target the treatment address emergence triple mutant the In and a more EGFR other mutant development the basis this mutant half patients own durable Together on wholly have end last by first parallel, benefit. plan the of form year. well candidate potential line into as to resistance month, of we're population planning to

discovery opportunities. we for advance programs, our and cancer R&D with from important research through as we're excited development, This On our Roche. with Medicines, our And now to additional Fouad to term. through the research as Research innovation research opportunities balance sustained leverage as clinic. we're collaboration of positioned that all medicines continue owned Overall, focus. phases risk back a to investigational immunotherapy transformative the by of last of of strengthens as about in efficiencies, entering Dr. EGFR company well registration. as all and achieved portfolio quarter the truly significantly position, strength into and platform, future wave of and as wholly development portfolio the welcome be other we global The we of We're end enable wholly progress strategic Namouni, focus programs organization, that owned discovery and XXXX progress three of being next integrated now platform, on generated will Fouad external is long fully this teams. diversification strong well programs, leading with as our that well growth financial the areas with over can our the increasingly across quarter, product our unified commercial key our front President invest and Development. make range growth And the Blueprint the overseeing a vision research

Christy? turn over commercial discuss to efforts. the call Now, Christy our to me let

Christy Rossi

mastocytosis. Jeff. commercial Thanks, us company. morning, Blueprint most course, the precision everyone. ongoing Through into progress forward set leading for we by avapritinib our as XXXX. ways, a that And, Growth the geographies. that systemic in head launch patients significantly phase bring from the incredible of quarter suffering driven into to Good Blueprint of fully this in be the our accomplishments integrated medicine front will In the QX efforts Medicines of GAVRETO; highlights footprint opportunity next stage global as new expansion in of many this to lens, is our journey growth by of the

Let's start with revenue.

product of with portfolio we the European therapies million. of precision Jeff are a globally. we driven and revenue, Commission US mentioned, patients $X.X GAVRETO AVYAKIT in As by of now US recognize Overall, AVYAKIT delivering million September, primarily approval of the approval $X.X for sales to

available revenue network reflects our We ordering of patients quarter in launch look independent specialty our to additional full select from late by Following quarter, our FDA approval, and GAVRETO QX of update. became early at forward sharing initial to first metrics primarily the pharmacies.

over Although received weeks, pleased as we several a feedback of available in variety from we've the it have early, GAVRETO commercially I've been the had the positive is field. stakeholders. with past

daily being ret and with for first has patients profile, have profile, deepened early as challenges with safety had responses, health uptake dosing, selective or clinical differentiated are time, treated in seen providers. well well in inhibitor predictable resonated sulfurcatnip. care includes tolerability who the who Our on a safety and We've as which manageable a patients once durable

at teams for have and practices. including closely actively community the initial in have and health We under pharmacists prescribers real with launch and an very anticipated sales exchange. ret The prescription the wins of large cancer, close under thyroid also time days also partners working with We've to as regional FDA systems. field combined four payers, about had positive testing, at the ready biomarker been team some ramp value up prescription Genentech broad our in review We've with GAVRETO on reaction our by a to teams to and educate bring collaboration rets GAVRETO launch. therapy our of seen oncology coverage are is the drive level fully identify time scientific which review currently also turnaround early had program. positive Their payer support from start we engaging is local trained patients, GAVRETO to average with formulary and now our

line to with utilization as by GIST. well Turning as late some AVYAKIT; patients unpromoted and seeing GIST consistent alpha PDGFRA are we driven utilization

DIXXX in to clinical trend world harboring or positively the Importantly, We of were PDGFRA studies. to we metastatic European also GIST are saw the and encouraged exceed treatment receive alpha for with real Commission to we continue patients thrilled what adult AVYAKIT for see approval unresectable mutation. durations

paradigm identifiable treatment about avapritinib we As As who Medicines. data geographical patients understanding for just treatment approach, that non the for we've suffer numbers especially disease in commercial of of for is approximately excited makes another advanced coupled SM in diagnose. launch excellence, of in as truly opportunity these the have the advanced line take markets from for top overstate but symptoms of mastocytosis. are a see Blueprint centers advanced are avapritinib These significant a finally, we chronic shared systemic we our line of focused we in our opportunity, duration commercial patients third sets. will with we foundation the announced disease and significantly September diagnosed third SM one mentioned, already top need miss a enabling also Jeff that can't XX,XXX with efforts And in data there, lives. deepened And major discussed one debilitating the great response in Europe their how future previously, that SM impact commercial rare our the targeting I

We and then to patients devastating disease, to make urgency the this with in globally. are first available with living working avapritinib US, commercially,

in patients critically, our is in cancer of launch the As support we And the of We growth us of for which commercial I'll our Europe. look GIST patients team I've efforts on GAVRETO lung to available we and we to commercially countries avapritinib the will efforts ahead in our Genentech. to non available focus our cell small turn look move AVYAKIT year. with hope US in is launch through updates. will continue to next US. and initiated in other of approval AVYAKIT in our to over in launch colleagues outlined. discuss at continue XXXX, our Germany, of now that QX and in truly to advancing in be forward collaboration financial We've thyroid Mike these finally forward eagerly exciting. into SM call anticipate drivers the The and growth up the we'll And support ramping making

Mike Landsittel

financial press Thanks in release. recorded we Christy. Earlier XXXX third results detailed quarter this morning, our

today's million total $XXX of the I'll touch recognize on third in few a financial quarter. For the We from revenues call, quarter. highlights

net record of pleased million are AVYAKIT As by sales. we Christy primarily to product mentioned, driven $X.X revenues,

upfront remains purchase sales $XXX Cost to approximately our collaboration recognize low we commercial pralsetinib. also with including milestone the collaboration We Roche we pre payment, payments continue as revenue, expense premium and work million off for in under approval. equity that inventory of

under cost and operating with total expenses quarter our sharing US Roche. profit driven by R&D sharing global to decreased Our collaboration compared the prior

continue we as expect well we quarter our quarter-over- in and our as BLU-XXX, programs discovery expense forward, as clinic. the see investments Looking advance towards EGFR avapritinib operating systemic our to advanced mastocytosis portfolio, with including modest to growth

cash have stock With We and Epson. for also the the Keystone the diverse on over multiple we have foreseeable term, with and our collaborations sales long including meaningful sources, are strategic Roche, company. provide a financial the product cash $X.X hand, in ever in billion future. and our strongest portfolio position across increases in royalty And non expense geographies, under four that multiple to and we anticipate looking as compensation potential based been payments partnerships major approximately revenue milestone significant

milestone next years. could existing year royalty payments approximately For from the example, million collaborations and over total per $XX average we that anticipate few

and are a call like forward to We portfolio. make continue look in we our would over updates questions. of size a company to now across position age, the you operator our for for further we and to unique With I to with as sharing turn Operator? the that, progress

Operator

first Our Frahm from of Marc comes the Instructions] line [Operator question from Cowen.

Marc Frahm

on a status expect of possible also talked give possibly Maybe you the you COVID know enrollment to then down. update you've about us when Can things and about complete but historically, FM. I Indolan the being end talked and there? this year do slowing

there? where are of kind just we So

Jeff Albers

take is This Sure. Jeff. I'll that.

the beginning release provide that XXXX. So we more will update at on detailed we've prepared provided statements enrollment of a in the in

where we seem startup sites spiking and lower. to particular some are be in the was come to where due region some about coming that on to cases are now other seem that talked to in As And cases, the slowed cases, cases they're some site unfortunately, on, the one I in it more add about to certainly sites, COVID. critical well. think now; as in we regions sites of continue was in of But previously, can be that, there

markers little all willingness So to of of we color are that. patient's the come a more But get there. want to on in engagement

of will really enrolled need year. better beginning we'll exact fully we a when of timing sense have optimistic, of So next the to but be at it be

Operator

of from Goldman comes Richte Sachs. the from line Salveen question next Our

Unidentified Analyst

a the maybe then that, data SM follow And Hi, everyone. particularly other And to portfolio, This taking able as for the trial? additional we follow hear is when up Thanks readouts to Andrea Salveen. for just for about more up. love to I question. follow see a from might cadence up on have would of be PATHFINDER the

Jeff Albers

Jeff, so I'll Sure, this is start.

just for our So guided provided September. in the first we Obviously, line next to top haven't -- we're the getting in we've data Obviously, SM of process foremost update. we the advanced together. a medical to pulled need we But specific updates guided in file on to at set also data nature conference, sNDA and timing. that more but provide we haven't fulsome certainly intend a and

Unidentified Analyst

combinations. with just you GAVRETO potential then indications the to Roche; And collaboration it. Got respect to the spoken had with about with explore additional or

those this into advancement how and when are Roche and might programs. right we you about wondering now, Just see thinking one of

Mike Landsittel

Yes, that. I'll take Andrea,

in with yes, to plan. colleagues how our at been out we're process over so collegial And of relationship So and very it's closely expand very Roche. working development accelerate a the where we accelerate the figuring are

in therapy, set single but both be Roche the We including in are out solid started as now the how to medicines, really retrospect pro NIM tumors an agnostic already in that would pursuing into study. with lines agent, the on -- move -- is And of of driven also indications tumor portfolio. arrow earlier actually as focus earlier importantly, a which combo other some

details as will I in we update will, so And think work the future. through these

Operator

comes Reni line from Benjamin of from JMP next the Securities. Our question

Reni Benjamin

morning, congrats GAVRETO happening of this guys. Thanks as just, need we the kind just like that? as little the mentioned that questions Germany; on the for we and late. product? in to jumped think the Hey, progress. about a early you I we the the related of You call ramp, there know Are drug, neck of with to Can thinking follow and this maybe then we commercialization I be considering differences good be EU? about And should onto what's all for but trajectory the it's [Indiscernible] neck taking

as how should get we Thank that. discussions specific And so are just other you. sense and the to how view emerging country to a wanted

Christy Rossi

is that. Yes, can Christy. I this Sure. take

there. the we're Lilly, about So the I really as the about seeing had I as lot to of we're data, great I the said, think progress taking. as that approach a seen from take thing excited the of we we've launch, we've we're we think well the expect biggest know that with patients If what GAVRETO reception is we that that attractive, as And will more and opportunity are right? that can mean, identified. patients far lot so there's continue out grow that from is as that more to ret I a that opportunity clearly

I the one in are to the see that since of new thyroid going anticipating as patient to difference a -- lung they're certainly on and on flow to starts approval extrapolate the patients But to now agent they ramp market. continue the start ramp available first continue And that. of think it's biggest as obviously when through. heels so we'll can't that look to opposed we new is then you are an agent only the we

forward look as more Europe to update. we provide on that that as to of question having And well. to data address QX then share So and a

just to were everyone's countries launch we we as to the the company market timelines Germany everyone's thrilled as as reimbursement commercial Blueprint of the around usually given really I dynamics, a that German have hurdle and is So the over come first think know biggest that emerged approval different have the I expect and market. is aware Clearly is gate securing really global sure out the I'm and aware pricing reimbursement underway; by now would other are time. online and

to coming having we -- in in will AVYAKIT for Europe, those PDGFRA in discussions mutant look are we So engaged commercially actively and months. the forward patients DXXXV available

Operator

to Leerink. question of Our Andrew next SVB the from line comes Berens

Andrew Berens

in two might approval regarding I store based have control you They're which ASM I probably which has how your a studies. FDA I versus think this the you're ask on in, what non-controlled wondering wanted full you trial. have process, will at look a the submission, -- both we regulatory which you Thanks. visited but a was submit. to guys know question past, Hi, the to about

Andy Boral

it's take I'll with seen really data Hey, in patients [Indiscernible]. is no, pretty advanced different dramatically what's than transformative avapritinib the so we that. Andy. been SM for think Yes, and

are track both actually to submit very with It's based EXPLORER with confident the on had consistent and that single we we're FDA So and had want submission study that while we've leukemia discussions in data the on approval. that they got and PATHFINDER I and data out the fourth system, be actually will set studies. sNDA well in randomized point [Indiscernible] in advanced with received. arm are to quarter confident a and

Operator

the line Our from from next comes Peter question of Barclays. Lawson

Peter Lawson

for taking question. thanks my Hey,

BLU-XXX the designs? mutant triple should about How drugs. when think those on and double thinking should I be the for Just initial we we EGFR both drugs? guess trial And data about

Jeff Albers

Sure, don't you Andy, why take that?

Andy Boral

Yes.

the So a kinase, really, just we're type as of to designed the since remind on potentially, truly mutations inhibiting about to the the target And wild resistance of resistance frontline combination prolong high that other be mutant really we provide not both mutant EGFR these with And is to can in the control, everyone common disease ban weltec developing of resistance we really known on inhibitor, most on this opportunity that profile all the type our setting exciting provide the triple both two think focused really, rates ESMO the potently combine emergence which And generation we EGFR preventing to following is specifically inhibitors, but really which sparing, by double benefit and a EGFR response with inhibit where BLU-XXX, from both you patients, inhibitor, what's also mechanisms. know, was directed the, pralsetinib. resistance in medicines, target situation resistance while the program they'll is very to EGFR first I wild also kinase. this think think important opportunity has treatment disease, agents.

first XXX a And So to the into we XXXX. year. are of mutant nominate we expect end advance to clinic the of the double by in the inhibitor half planning

Jeff Albers

is as this on data [Indiscernible] potential I first on from that move early based the maximize move laid that, Jeff, the into prevent agent as exciting the we therapies that program. the that And interesting as enthusiasm two profile the there's these establishing just from and been growing is resistant has just think this to as efficiently really single as underscore Andy much a investigators internally, agent, to and that perspective ability the effectively those and Virtual single And opportunity, combine safety then but programs something at well possible. and to it's been forward summarized as Andy share really Media, lines to and out durability engagement

Operator

comes from the next from Morgan Stanley. David line question Our of Lebowitz

David Lebowitz

at entry taking you much do this coming to commercialization recent fully the ramped launch Thank GAVRETO up partnership, it expect very partnership state entered, say given would will my was look effort closely vis-à-vis for steady the is in the how you you question. more When or one. Roche point, of the the you at initial the evolve

Christy Rossi

Sure. Yes.

specific engine the said, and both engaging. and well sure make of out local that they working national certainly So tech collaborate a course, as of we're teams and Roche partners. level capabilities at And we're have to as trained are engagements to level fully I been the utilizing on a at

the effort say ramped up. So I would is

Of the as of to things launch, flexible you to information. and go through be and you one is more as adapt course, learn nimble critical a

would engaged. excited sure So that. we really we both like got about do teams I'm But And fully with any products. we're do we've will that,

Jeff Albers

on be there to got value realizes together a indication is these where add be continued the just going from I And going If then coming. Jeff. and ultimately, to the additional we've that really teams that think it's obviously too, is working we patient This thyroid identification. because evolution two

So realization that of of a maximizing of a opportunity. be more will sort gradual that

David Lebowitz

expect physicians understanding guess, up at ret with come this people that it quarter. and point? mind, testing positive in and is other in this is point ret small approval non alterations targeted you ret will, for that since indications therapy, MTC How deal cell and I first the could in do yes, come fusions that With

Christy Rossi

that We a clinical in see that go preparing think education hopeful So anticipate focused alterations then certainly well, the I for which we're approval, do and as see and that's perspective. to focus. certainly place would certainly be that's really would in driving We around in primarily we And thyroid, our a from indications is shared ret not future other commercial not focus that on a right non there, there. but data respect. obviously and utilization be small commercial ready some will so we're near now that, lung we we may cell

David Lebowitz

how And the Sure. with the operating recent second certainly quite then kind question, first last middle, should we the a think second in as of from -- in quarter R&D bit Would what the SG&A, a we given should of expenditures spend both and run the going first being forward? the dropped right level quarter think be as partnership, third? to quarter of it rate closer is quarter, far or

Mike Landsittel

to one? take Hey, Mike, want you do that

Mike Landsittel

Yes, thanks. Yes. Mike. This is

I the cost well cost of sharing what in sharing impact Roche R&D think you profit global third the US from the So was quarter as the sharing saw the as collaboration.

caused And expenses for or QX. reset so that are a operating of clinical

specific But from quarter- the I maybe unlike; to want just will lower over trend forward, level cost impact the we going not quarter. year increases, over-quarter think be sharing. resetting quarter-on-quarter modest see to think past profit or since will we have the saw don't the a around it so a I growth, point and we of we that

Operator

the comes question next line Sandler. Raymond of from from Our Chris Piper

Nicole Gabreski

Gabreski question. is on for thanks taking This Nicole for and the morning, Chris. Good

So on of the maybe with other some following the up one just pipeline, questions.

those is detail certain candidate? Thanks. second EGFR double where BLU-XXX. curious, three this the development there can the I potential And just about mutant more to third to new know candidates as guys of expect I'm be around a development will about venue because we well And EGFR candidate, the mutant potentially a disclosing as year. one more double hear I So candidate. you is talked But up know have

Jeff Albers

Sure. This is that. I'll Jeff, take

candidate of happen sort think in safely mutant as going they're for will in guidance of sort together development to of we could reset of terms team in to preclinical early in is and that you data, provide the later we the guided venue will the for assume haven't all venue, do program goals quarter. third every So the terms we'll in think XXXX. double pulling to happen that's likely a QX I where It year, I

what QX where is. program think I would early is we So what announce that

Operator

question the Dane next Raymond of Leone from Our comes from James. line

Dane Leone

for taking our Hi, here. thanks questions

just I jam two here. I'll together So guess

Firstly, when clinical started regarding adjuvant do how half put as moving it's running you market study actually osimertinib about terms BLU-XXX? of BLU-XXX then you. and get basically, ISM, could and site what's opportunity think Hereditary you're then in Is that SM, and some more Alpha the contexts would you that's thinking Thank secondly, maybe And syndromes, to and just HATS, Tryptasemia and study? how now to patients, you the standpoint? with the that about in the thinking the regulatory year for are to checklist market Syndrome incremental avapritinib opportunity, ASM first called. as the And about the mass XX,XXX activation opportunity and more in like listed cell or from a

Jeff Albers

why to don't for take it Andy over probably first question, you the pass then Christy, question. So I'll second the

Christy Rossi

Sure.

emerging thinking avapritinib about disorders, more the profile broadly maybe there expand cell in and emerges opportunity as moving think first excited in as to our we're penetrate even into I labeling, about I ISM there, indolan dosing, franchise to really solidify really BLU-XXX, optimize potential ISM. is, sort opportunity. well. able that be that's to forward, the for the to think And are we very the So And data about emerging an we're of very in pioneer, mass and as obviously rapidly

that can we like the BLU-XXX of group we lifelong about And said excited optimize profile then before cell treatment. also really we're as and there diseases so really investigating And that. we feel are in require for chronic a disorders, other mass

those Andy So forward, I Boral. and it will we'll of turn be moving both to

Andy Boral

first. So take your maybe I'll second

components, to the of final the study -- other track So work XXX course, first the that begin and we're be clinic, for the necessary next to in on and into are on submit tasks clinical the steps the and IND just year. and it's working half will getting of IND non we

a or we probably in unusual, that's osimertinib, actually, that a back interact metastatic thinking osimertinib opportunity, going their generation pretty when first we progression, XXX specific that some offers nothing they osi front goes I think definitely EGFR to think because with, the experts there. inhibitor. a those as for will they I to now to interesting think use lot cancer people a I there's go is adjuvant lung fact, as progress in patients, that there's of And on talked of initial

again, order. you back that mutant risk to triple the so the actually the opposite in gets And with drugs

opportunity be that for we an could study. BLU-XXX in So think the

Jeff Albers

advanced impact Agivent as in us And to pralsetinib non activity as And we systemic position how following And the milligrams patients of within year, were those that foot be seeing two we two form of strength. as at paradigm from the year advanced and effective, Roche collaboration. are the playing XX,XXX in sort as really about mastocytosis, sort is from think really out really of of EGFR unfolded, how I'll when building you or our and treated into think moving XXX the XXX look for for time programs Medicines, provide half disease go a the the different currently. in to osimertinib And articulated ret lung form Blueprint the will strong playbook starting lot the development that osimertinib development building we're we then maybe future priority. cancer, of about perspective. understand disease, regardless our have how level, a of position moving as characterize get clearly questions today of the where we talked has underscores an evolution if opportunity, treatment earlier this in avapritinib the milligram a into point. out that on, we confident in merge why the about investments round when driven so on that you is of well flexibility we XX at had early made to where a it could the took often and And setting EGFR gives of than him think the a of lines, of rather back piece Similarly, gives then into will I we then we together, that of the puck

portfolio it the there you time, where be still strong opportunities about that a of in mass diseases, evolves and benefit. whether Christy as all invest position the be here there's to at financial cell so other expanding indolent that if in play is SM but over or said how allows us are need with patients continue in potential think patient to greatest And the provide

Operator

line Our next Lee of from question comes Arlinda Canaccord. from the

Arlinda Lee

I about also, question. penetrant? my trial. on not SM also talk mentioned briefly taking that. for can into I'm other skating miss that a talk couple; that thanks you were what's you you XXX, have for avapritinib. Can when brain the for guys, one then initiate said to And about you filing curious planning the And -- I Hi, elements on went was it you XXX? design And Thanks.

Jeff Albers

advanced on those? of to take So then SM and XXX? want Andy, filing do avapritinib Sure. you characteristics

Andy Boral

Yes.

writing other ISM so the first we're trial, terms it's on in track we hand, the study it for into And to the of the and of process an year. barrier hypothetical. brain and very from as not so benefit, really to other are but couple on obviously, be bit distinction this doing dose to priority go data just to of dose that terms for appropriate determining the, Arlinda, is first will the that's the start, some patients started just actually half also together. BLU-XXX of which volunteer remains this designed And haven't offer the COVID-XX; getting of the the more the the important enzymes the a a we few high potential final, that'll data data we all do study the, year cross have fronts, XXX, so selectivity what ISM, for are the the when avapritinib. ISM, key that what's now would or very range guided blood a in that a on that's healthy mentioned, we get ISM specifically we're on despite together. in potentially, again, dose get happy us. to in filing the track parts end to provide documents first by for specifically final of and So all fair kind of think that bit it's thing, of there's of year, for you a And, It as with but gaining filing, the but in

Operator

from of question Guggenheim. comes line Schmidt the Michael next of Our

Michael Schmidt

had thanks one taking AVYAKIT. guys, I on Hey, for just questions. my

treated. How potentially And is confirm of non quarter think versus maybe use. the about point? and just ASM broadly, that bit? promoted Your mentioned quantify Could I some much Can this you you already more sales at that patients patients you a suggest that? XXX little in in third

Christy Rossi

that. take Sure. I'll

obviously, patients details late complex, [Indiscernible] going continue I'm seeing durations, are So alpha for the option happy exactly got patients that to get when is not on when just on durations, matter and PDGFRA pleased to start, line patients, treated, many have we available see growth into you and continuing see we're we patients have you've how shorter quite we've to but driven kit just therapy, we patients. to overall, long see revenue very to

of on terms we patients we're challenging get to exact same. to said these relying can as make feedback mix, that, patients, In do but try prescribers may coding I is it's primarily before, from estimates, quantifying the and for the the we

utilization in that have to see not certainty, we're late so know say able line. And we guidelines to clearly to we in a be listing with a continue position just

still know very is that need we and the high. unmet Just patients in

Michael Schmidt

around been those has some physicians, drugs, then now what absence then feedback the the lung just two cancer side TKI QTC of the but differentiating initial effects and Understood, Christy, weeks, And a maybe efficacy now frequencies? and specifically, dosing realized been prolongation. has what potential on feedback of with of wondering from available, some market in two only and and GAVRETO of been is differences the the few with

Christy Rossi

yes. Sure,

think said, very, I as very the So positive. been, has I feedback

to community's of not for effective available had all, the have first thrilled therapies think, available I the have today. patients, treatments that right,

utilization both I used think, agents, to be see GAVRETO was to effective. going highly very of think I we're

maybe I may to these that I real early I we've of some of world. different both side more the see require is hypersensitivity think again, are think that I with just TTC days, things versus of mentioned, it's one, difference mean effects continued that approach, agents. in about the safety, I certainly hear management is sort oncologists some I think you is And, and the think you another, again probably is prescribing where of the think, wheelhouse that's that idea something comforting as in

feedback as to And is so emerge will profile and I perspective think of that been world is important, the The think, remember from non clinical last get get sort I around what we to clinical also happy that have over the efficacy utilization. right. profile of aspects to real very we've safety that piece, to both you start very that time, the continue an are

dosing, daily again, person called else, like one had to still like once issues. to we everybody So in which us get back but oncologist, oncologist fact, I say and around

well being very again, taken, important. their And that prioritized, really dispensing retain treatment we've received. practices is and of And approach been able which the is has and patients simplicity pharmacies, so control to

Operator

David question Nierengarten next comes of line Securities. the Wedbush from from Our

David Nierengarten

question. I'll new Hi, interpretation the one just name. of thanks with the --

-- agent couple a as other, the mentioned dynamics Or on Or basically payers, sorry, to believe preference formulary Or that's and is I other the on is I are they it the there GAVRETO? they formularies? Thanks. for was this one treated regarding curious equally? wins, are over formularies the is equal? You Are remarks. a prepared over it in they the preferring one

Christy Rossi

Sure.

can covered also different of very the practices of another. Health approach cetera and drive who that this therapy System at preferential selection space, group it's within what broader support fighting again, able them system the choice some we; that able a levels a of that So different important word when want oncology. very are the formulary often have at utilization be taken. but being think have formulary of et many certainly access; connotations, approach one been will focus see well are again payers, more right, in we've I may do And community be dynamics, at been will clear practices, what et seen and we patients, now incredibly distribution and think interesting from access to that value drive it think becoming prevent you there's practice quality pricing strategy really care given cetera are happy taken, we And for want aspects payer that agents, over I that level, of around most there received. that to is allows payers, GAVRETO. on and certainly we've there's With a cost into expect. the therapies, I certainly to frankly, pharmacies broad level, both in we has most The measures to by community are and that to that patients with we've that dynamics integrated have their healthcare that And would

seeing we're another some preference is place where that being So driven.

Operator

Thank the over Albers you. to turn remarks. At closing this to call would for further time, like back I'm showing Jeff questions. I no

Jeff Albers

and employees in preclinically; to that by the now strong in on well support encouraged on. time the is processes And time. look continue that we we reflect operator, during and at setup really they then and focus also rewarding all I'm quarter the difficult of us we this a now. we of as a and the the like a really ways we with to we're as regulatory to year. over to their appreciative to continue be we're I We have on in for medicine remainder Obviously, the started, commercial position taking everyone undertaking, Medicines continued thanks the have again, we're execute Medicines. Blueprint continue kept know feel getting this work Thanks, forward and adding to as a feedback really investigational for Blueprint thinking just based the components. lot been about And forward looking And

providing to Thanks future forward a great look So day. Have updates. lot. a

Operator

and this participating. calls. you Ladies concludes today's for gentlemen, conference Thank

may You now disconnect.

Blueprint Medicines (BPMC) 29 Oct 202020 Q3 Earnings call transcript